NCT00899795View on ClinicalTrials.gov

Evaluating Cell Damage in Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, or Fanconi Anemia; in Patients Who Were Exposed to Alkylating Agents; and in Healthy Volunteers

CompletedOBSERVATIONAL
Enrollment

35

Participants

Timeline

Start Date

June 30, 2002

Primary Completion Date

October 31, 2010

Study Completion Date

October 31, 2010

Conditions
LeukemiaMyelodysplastic Syndromes
Interventions
GENETIC

cytogenetic analysis

GENETIC

fluorescence in situ hybridization

OTHER

flow cytometry

PROCEDURE

biopsy

Trial Locations (1)

97239-3098

OHSU Knight Cancer Institute, Portland

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

OHSU Knight Cancer Institute

OTHER

NCT00899795 - Evaluating Cell Damage in Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, or Fanconi Anemia; in Patients Who Were Exposed to Alkylating Agents; and in Healthy Volunteers | Biotech Hunter | Biotech Hunter